133839-56-2

Upstream product

• 71126-73-3 6-benzyloxyhexan-1-ol 
• 629-11-8 1,6-hexanediol 
• 100-39-0 benzyl bromide 
• 54247-27-7 1-bromo-6-benzyloxyhexane 
• 603-35-0 triphenylphosphine 

Downstream Products

• 133839-67-5 1-(2-Benzyloxy-6-hydroxyphenyl)-3-hydroxy-9-phenylnonan-1-one 
• 133839-74-4 (E)-1-(2-Benzyloxy-6-hydroxyphenyl)-9-phenyl-2-nonen-1-one 
• 133839-72-2 1-(2,6-Dihydroxyphenyl)-3-hydroxy-9-(3,4-methylenedioxyphenyl)nonan-1-one 
• 133839-71-1 1-(2-Hydroxy-6-methoxyphenyl)-3-hydroxy-9-(3,4-methylenedioxyphenyl)nonan-1-one 
• 133839-78-8 (E)-1-(2-Hydroxy-6-methoxyphenyl)-9-(3,4-methylenedioxyphenyl)-2-nonen-1-one 
• 114226-25-4 1-(2-methoxy-6-hydroxyphenyl)-9-(3',4'-methylenedioxyphenyl)nonan-1-one 
• 133839-80-2 1-(2,6-Dihydroxyphenyl)-9-(3,4-dimethoxyphenyl)nonan-1-one 
• 133839-79-9 1-(2,6-Dihydroxyphenyl)-9-(4-methoxyphenyl)nonan-1-one 
• 133839-64-2 7-(3,4-dimethoxyphenyl)-heptan-1-al 
• 133839-62-0 7-(3,4-Dimethoxyphenyl)-heptan-1-ol 
• 133839-59-5 (Z)-1-Benzyloxy-7-(3,4-dimethoxyphenyl)hept-6-ene 
• 133839-58-4 (Z)-1-Benzyloxy-7-(4-methoxyphenyl)hept-6-ene 
• 133839-57-3 (Z)-1-Benzyloxy-7-phenylhept-6-ene 
• 133839-60-8 (Z)-1-Benzyloxy-7-(3,4-methylenedioxyphenyl)hept-6-ene 

Relevant academic research and scientific papers

Stereoselective total synthesis of siladenoserinols A and D

The stereoselective total synthesis of siladenoserinols A and D has been accomplished using carbohydrate as a chiral template. The feature of this work is to build the medicinally privileged 6,8-DOBCO scaffold through a cascade reaction of hydrogenation/deacetalization/ketalization in a one-pot process, that is, to take advantage of a thermodynamically controlled bicyclization of polyhydroxyketone under HCl/MeOH reaction conditions. The current cost-effective synthetic strategy could facilitate the bioactivity investigation of siladenoserinols.

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

Organoselenium-catalyzed synthesis of oxygen- and nitrogen-containing heterocycles

A new and efficient approach for the synthesis of oxygen and nitrogen heterocycles by organoselenium catalysis has been developed. The exo-cyclization proceeded smoothly under mild conditions with good functional group tolerance and excellent regioselectivity. Mechanistic studies revealed that 1-fluoropyridinium triflate is key for oxidative cyclization.